A Phase 3 interventional study of Lixisenatide (AVE0010) and Self-injector pen device (OptiClik®) in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 82 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-14.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing lixisenatide in Diabetes Mellitus, Type 2 — 1 open to participants now, 2 under way, none of them phase 3. lixisenatide · Diabetes Mellitus, Type 2.
Among the 47 studies testing lixisenatide in Diabetes Mellitus, Type 2, this one is the 16th largest by enrollment, is one of 4 that started in 2012, is one of 29 in phase 3, and was the 16th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 47 studies testing lixisenatide in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
By country, each count listing its studies:
lixisenatide: first FDA approval 2016 (ADLYXIN), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 451 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 321 across the 47 interventional studies. Of the 43 that completed or were terminated, 23 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 47 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 58th largest by enrollment of the 178 interventional ones that give a count, is one of 10 that started in 2012, is one of 80 in phase 3, and was the 107th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing lixisenatide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objective:
To assess the effect of the 2 lixisenatide regimens on:
The maximum study duration was 28 weeks per participant, including a 24-week randomized treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lixisenatide 10 mcg once daily (QD) within 1 hour before "main meal of the day" for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24.
Drug: Lixisenatide (AVE0010) · Device: Self-injector pen device (OptiClik®) · Drug: Metformin
Lixisenatide 10 mcg QD within 1 hour before "breakfast" for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24.
Drug: Lixisenatide (AVE0010) · Device: Self-injector pen device (OptiClik®) · Drug: Metformin
Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
To be kept at stable dose (≥1.5 g/day) throughout the study.
Also known as: Route of administration: Oral
Change in HbA1c From Baseline to Week 24
Change in HbA1C was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using last observation carried forward (LOCF). On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline HbA1c assessment during on-treatment period.
Time frame: Baseline, Week 24
Percentage of Participants With HbA1c Level <7 % or ≤6.5% at Week 24
Here, number of participants analyzed = participants with baseline and at least one post-baseline HbA1c assessment during on-treatment period.
Time frame: Week 24
Change in Average 7-point SMPG Profiles From Baseline to Week 24
Participants recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime two times in a week before baseline, before visit Week 8, before visit Week 12 and before visit week 24. The average value across the profiles performed in the week a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to the day of last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline 7-point SMPG assessment during on-treatment period.
Time frame: Baseline, Week 24
Change in FPG From Baseline to Week 24
Change in FPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to 1 day after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline FPG assessment during on-treatment period.
Time frame: Baseline, Week 24
Change in Body Weight From Baseline to Week 24
Change in body weight was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline body weight assessment during on-treatment period.
Time frame: Baseline, Week 24
Percentage of Participants Who Reached the Target of HbA1c <7% at Week 24 And Did Not Experience Confirmed Symptomatic Hypoglycemia (Plasma Glucose [PG] <60 mg/dL [3.3 mmol/L]) During 24-Week Treatment Period
Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemic episode with an accompanying PG\<60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate if no PG measurement was available. On-treatment period for symptomatic hypoglycemia assessment was defined as time from first dose of study drug up to 1 day after last dose of study drug. Participants without any post-baseline on-treatment value for HbA1c were counted as non-responders if they experienced at least one symptomatic hypoglycemia. Otherwise, they were counted as missing.
Time frame: Week 24
Percentage of Participants Who Reached the Target of HbA1c <7% And Had No Body Weight Gain at Week 24
Participants without post-baseline on-treatment values for (HbA1c and body weight) that were no more than 30 days apart were counted as non-responders if at least one of the components (HbA1c and/or body weight) was available and showed no response. Otherwise, they were counted as missing.
Time frame: Week 24
Percentage of Participants Who Reached the Target of HbA1c <7% And Had No Body Weight Gain at Week 24 And Did Not Experience Confirmed Symptomatic Hypoglycemia (PG<60 mg/dL [3.3 mmol/L]) During the 24-Week Treatment Period
Participants without post-baseline on-treatment values (for HbA1c and body weight) that were no more than 30 days apart not more than 30-days apart were counted as non-responders if at least one of components (HbA1c and/or body weight) was available and showed no response. Otherwise, they were counted as missing.
Time frame: Week 24
Percentage of Participants Who Reached the Target of HbA1c <7% And Had a 2-hour Postprandial Plasma Glucose (PPG) <140mg/dL After Breakfast or Main Meal At Week 24
On-treatment period for 2-hour PPG assessment was defined as the time from the first dose of study drug up to the day of last dose of study drug. Participants without post-baseline on-treatment values (for HbA1c and 2-hour PPG) that were no more than 30-days apart were counted as non-responders if at least one of the components (HbA1cand/or 2-hour PPG) was available and showed no response. Otherwise, they were counted as missing.
Time frame: Week 24
Change in Diabetes Treatment Satisfaction Questionnaire Score (DTSQs) From Baseline to Week 24
DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1, 4, 5, 6, 7 and 8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction. On-treatment period for treatment satisfaction assessment was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug. Missing data was imputed using LOCF. Here, number of participants analyzed = participants with both baseline and Week 24 DTSQ score assessment during on-treatment period.
Time frame: Baseline, Week 24
The study was conducted at 82 centers in 10 countries. A total of 734 participants were screened between February 15, 2012 and October 16, 2012. 283 participants were screen failures; main reason for screen failure was that glycosylated hemoglobin (HbA1c) values were out of protocol defined range. 451 participants were randomized.
| Milestone | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| Started | 225 | 226 |
| Completed | 189 | 202 |
| Not completed | 36 | 24 |
| Withdrew: Adverse event | 10 | 11 |
| Withdrew: Lack of efficacy | 10 | 5 |
| Withdrew: Poor compliance to protocol | 8 | 3 |
| Withdrew: Other than specified above | 8 | 5 |
Change in HbA1C was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using last observation carried forward (LOCF). On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline HbA1c assessment during on-treatment period.
| Percentage of hemoglobin | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| Change in HbA1c From Baseline to Week 24 | -0.65 ± 0.074 | -0.74 ± 0.074 |
Here, number of participants analyzed = participants with baseline and at least one post-baseline HbA1c assessment during on-treatment period.
| Percentage of participants | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| HbA1c <7% | 43.6 | 42.8 |
| HbA1c ≤6.5% | 22.5 | 25.7 |
Participants recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime two times in a week before baseline, before visit Week 8, before visit Week 12 and before visit week 24. The average value across the profiles performed in the week a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to the day of last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline 7-point SMPG assessment during on-treatment period.
| mmol/L | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| Change in Average 7-point SMPG Profiles From Baseline to Week 24 | -0.80 ± 0.145 | -1.10 ± 0.145 |
Change in FPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to 1 day after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline FPG assessment during on-treatment period.
| mmol/L | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| Change in FPG From Baseline to Week 24 | -0.35 ± 0.192 | -0.57 ± 0.193 |
Change in body weight was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline body weight assessment during on-treatment period.
| kg | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| Change in Body Weight From Baseline to Week 24 | -2.60 ± 0.320 | -2.80 ± 0.319 |
Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemic episode with an accompanying PG\<60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate if no PG measurement was available. On-treatment period for symptomatic hypoglycemia assessment was defined as time from first dose of study drug up to 1 day after last dose of study drug. Participants without any post-baseline on-treatment value for HbA1c were counted as non-responders if they experienced at least one symptomatic hypoglycemia. Otherwise, they were counted as missing.
| Percentage of participants | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| Percentage of Participants Who Reached the Target of HbA1c <7% at Week 24 And Did Not Experience Confirmed Symptomatic Hypoglycemia (Plasma Glucose [PG] <60 mg/dL [3.3 mmol/L]) During 24-Week Treatment Period | 40.4 | 41.0 |
Participants without post-baseline on-treatment values for (HbA1c and body weight) that were no more than 30 days apart were counted as non-responders if at least one of the components (HbA1c and/or body weight) was available and showed no response. Otherwise, they were counted as missing.
| Percentage of participants | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| Percentage of Participants Who Reached the Target of HbA1c <7% And Had No Body Weight Gain at Week 24 | 40.8 | 38.6 |
Participants without post-baseline on-treatment values (for HbA1c and body weight) that were no more than 30 days apart not more than 30-days apart were counted as non-responders if at least one of components (HbA1c and/or body weight) was available and showed no response. Otherwise, they were counted as missing.
| Percentage of participants | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| Percentage of Participants Who Reached the Target of HbA1c <7% And Had No Body Weight Gain at Week 24 And Did Not Experience Confirmed Symptomatic Hypoglycemia (PG<60 mg/dL [3.3 mmol/L]) During the 24-Week Treatment Period | 38.1 | 37.2 |
On-treatment period for 2-hour PPG assessment was defined as the time from the first dose of study drug up to the day of last dose of study drug. Participants without post-baseline on-treatment values (for HbA1c and 2-hour PPG) that were no more than 30-days apart were counted as non-responders if at least one of the components (HbA1cand/or 2-hour PPG) was available and showed no response. Otherwise, they were counted as missing.
| Percentage of participants | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| Percentage of Participants Who Reached the Target of HbA1c <7% And Had a 2-hour Postprandial Plasma Glucose (PPG) <140mg/dL After Breakfast or Main Meal At Week 24 | 28.9 | 27.6 |
DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1, 4, 5, 6, 7 and 8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction. On-treatment period for treatment satisfaction assessment was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug. Missing data was imputed using LOCF. Here, number of participants analyzed = participants with both baseline and Week 24 DTSQ score assessment during on-treatment period.
| Units on a scale | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| Change in Diabetes Treatment Satisfaction Questionnaire Score (DTSQs) From Baseline to Week 24 | 3.01 ± 0.546 | 3.54 ± 0.529 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 171) regardless of seriousness or relationship to investigational medicinal product (IMP).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lixisenatide Main Meal | — | 7/225 (3.1%) | 65/225 (28.9%) |
| Lixisenatide Breakfast | — | 7/226 (3.1%) | 60/226 (26.5%) |
| Event | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| Renal colicRenal and urinary disorders | 2/225 | 0/226 |
| CellulitisInfections and infestations | 1/225 | 0/226 |
| Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/225 | 0/226 |
| Myocardial infarctionCardiac disorders | 1/225 | 0/226 |
| Peripheral arterial occlusive diseaseVascular disorders | 1/225 | 0/226 |
| Cystitis noninfectiveRenal and urinary disorders | 1/225 | 0/226 |
| Postoperative wound infectionInfections and infestations | 0/225 | 1/226 |
| Cerebral infarctionNervous system disorders | 0/225 | 1/226 |
| Atrial fibrillationCardiac disorders | 0/225 | 1/226 |
| Abdominal herniaGastrointestinal disorders | 0/225 | 1/226 |
| Event | Lixisenatide Main Meal | Lixisenatide Breakfast |
|---|---|---|
| NauseaGastrointestinal disorders | 33/225 | 35/226 |
| NasopharyngitisInfections and infestations | 22/225 | 16/226 |
| HeadacheNervous system disorders | 8/225 | 16/226 |
| HypoglycaemiaMetabolism and nutrition disorders | 15/225 | 7/226 |
| Age, Continuous(years) | Lixisenatide Main Meal | Lixisenatide Breakfast | Total |
|---|---|---|---|
| Mean | 56.3 ± 10.6 | 57.5 ± 9.7 | 56.9 ± 10.2 |
| Sex: Female, Male(Participants) | Lixisenatide Main Meal | Lixisenatide Breakfast | Total |
|---|---|---|---|
| Female | 124 | 129 | 253 |
| Male | 101 | 97 | 198 |
| Race(participants) | Lixisenatide Main Meal | Lixisenatide Breakfast | Total |
|---|---|---|---|
| Caucasian/White | 211 | 211 | 422 |
| Black | 4 | 8 | 12 |
| Asian/Oriental | 10 | 7 | 17 |
| Ethnicity(participants) | Lixisenatide Main Meal | Lixisenatide Breakfast | Total |
|---|---|---|---|
| Hispanic | 11 | 12 | 23 |
| Non-Hispanic | 214 | 214 | 428 |
| Number of Participants with Categorical Body Mass Index (BMI)(participants) | Lixisenatide Main Meal | Lixisenatide Breakfast | Total |
|---|---|---|---|
| <30 kg/m^2 | 51 | 60 | 111 |
| ≥30 kg/m^2 | 174 | 166 | 340 |
| BMI, Continuous(kg/m^2) | Lixisenatide Main Meal | Lixisenatide Breakfast | Total |
|---|---|---|---|
| Mean | 33.47 ± 4.50 | 32.77 ± 4.62 | 33.12 ± 4.57 |
| HbA1c(Percentage of hemoglobin) | Lixisenatide Main Meal | Lixisenatide Breakfast | Total |
|---|---|---|---|
| Mean | 7.85 ± 0.76 | 7.93 ± 0.78 | 7.89 ± 0.77 |
| Fasting Plasma Glucose (FPG)(mmol/L) | Lixisenatide Main Meal | Lixisenatide Breakfast | Total |
|---|---|---|---|
| Mean | 9.22 ± 2.03 | 9.31 ± 2.04 | 9.26 ± 2.03 |
4 further baseline measures are reported on the registry.
The record gives a start of Feb 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 3 years 5 months after primary completion. A results delay was requested in May 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lixisenatide · Metformin